Precision BioSciences Inc DTIL:NASDAQ

Last Price$1.59NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/13/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$1.65 (1)
Ask (Size)$1.69 (1)
Day Low / HighN/A - N/A
Volume201.00
 

View Biotechnology IndustryPeer Comparison as of 05/13/2022

 

Precision BioSciences Inc ( NASDAQ )

Price: $1.59
Change: +0.07 (4.61%)
Volume: 201.00
4:00PM ET 5/13/2022
 
 

Brainstorm Cell Therapeutics Inc ( NASDAQ )

Price: $2.72
Change: +0.01 (0.37%)
Volume: 500.00
4:00PM ET 5/13/2022
 
 

NextCure Inc ( NASDAQ )

Price: $3.54
Change: -0.08 (2.21%)
Volume: 175.6 K
4:00PM ET 5/13/2022
 
 

9 Meters Biopharma Inc ( NASDAQ )

Price: $0.38
Change: -0.004 (0.95%)
Volume: 5.6 K
4:00PM ET 5/13/2022
 
 

Champions Oncology Inc ( NASDAQ )

Price: $7.48
Change: +0.10 (1.36%)
Volume: 2.0 K
3:59PM ET 5/13/2022
 

Read more news Recent News

-- Earnings Flash (DTIL) PRECISION BIOSCIENCES Reports Q1 Revenue $3.3M, vs. Street Est of $5.78M
7:01AM ET 5/09/2022 MT Newswires

...

Goldman Sachs Adjusts Precision BioSciences' Price Target to $5 from $12, Keeps Neutral Rating
10:52AM ET 3/16/2022 MT Newswires

Precision BioSciences (DTIL) has an average rating of outperform and price targets ranging from $5 to $20, according to analysts polled by Capital IQ. (MT...

Precision BioSciences FY 2021 Loss Narrows, Revenue Increases; Shares Fall
12:31PM ET 3/15/2022 MT Newswires

Precision BioSciences (DTIL) reported a 2021 net loss Tuesday of $0.52 per diluted share, compared with a loss of $2.09 per share a year earlier. Analysts...

BTIG Adjusts Precision BioSciences' Price Target to $20 From $16, Reiterates Buy Rating
9:37AM ET 12/13/2021 MT Newswires

Precision BioSciences (DTIL) has an average rating of outperform and price targets ranging from $11 to $24, according to analysts polled by Capital IQ. (MT...

Company Profile

Business DescriptionPrecision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC. View company web site for more details
AddressDibrell Building
Durham, North Carolina 27701
Phone+1.919.314.5512
Number of Employees127
Recent SEC Filing05/12/20224
President, Chief Executive Officer & DirectorMichael Amoroso
Vice President-Operations & Information TechnologySinu Bhandaru
Chief Financial OfficerJohn Alexander Kelly
Chief Technology OfficerJeff Smith

Company Highlights

Price Open$1.58
Previous Close$1.59
52 Week Range$1.49 - 14.38
Market Capitalization$98.9 M
Shares Outstanding62.2 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/11/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.75
Beta vs. S&P 500N/A
Revenue$10.9 M
Net Profit Margin-34.69%
Return on Equity-45.55%

Analyst Ratings as of 05/05/2022

Buy
6
Overweight
1
Hold
2
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset